COVID-19 in a Down Syndrome Newborn
| Autor: | Katiane da Costa Cunha, Samela Miranda da Silva, Rodrigo Santiago Barbosa Rocha, Alexandre Ferreira da Silva, Aurimery Gomes Chermont, Bianca Duarte de Oliveira, Gabriela Caroline Lobato Pontes, Daniel Figueiredo Alves da Silva, Ariella Cristina Rego Lobato, Tallita Olga Calvinho Martins |
|---|---|
| Rok vydání: | 2020 |
| Předmět: |
0301 basic medicine
medicine.medical_specialty Down syndrome Leukopenia business.industry medicine.disease Intensive care unit law.invention 03 medical and health sciences 030104 developmental biology 0302 clinical medicine medicine.anatomical_structure law Clarithromycin Internal medicine medicine Gentamicin Neonatology medicine.symptom Trisomy business 030217 neurology & neurosurgery Nose medicine.drug |
| Zdroj: | International Journal of Clinical Pediatrics. 9:116-119 |
| ISSN: | 1927-1263 1927-1255 |
| DOI: | 10.14740/ijcp396 |
| Popis: | A 36-week premature newborn with trisomy 21, had a fever, runny nose and mild dyspnea at 27 days old. Parents had flu-like symptoms. He was admitted to intensive care unit (ICU), in isolation with support therapy. His reverse transcription-polymerase chain reaction (RT-PCR) test for coronavirus disease 2019 (COVID-19) was positive. He had leukopenia and lymphopenia and increased C-reactive protein (CRP) levels, associated with mixed and interstitial opacities on chest radiography. Antibiotic therapy was performed with ampicillin and gentamicin for 10 days. He had improvement of symptoms, with worsening of CRP levels. On the 11th day of hospitalization antibiotic therapy was replaced by clarithromycin, which was performed for 5 days, with laboratory improvement after introduction. Chest computed tomography (CT) showed bilateral ground-glass lesions. He had a good recovery and was discharged from hospital with 17 days of hospitalization. Int J Clin Pediatr. 2020;9(4):116-119 doi: https://doi.org/10.14740/ijcp396 |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|